| Title |
Rationale for the prevention of syncope trial IV: assessment of midodrine
|
|---|---|
| Published in |
Clinical Autonomic Research, May 2012
|
| DOI | 10.1007/s10286-012-0167-5 |
| Pubmed ID | |
| Authors |
Satish R. Raj, Peter D. Faris, Maureen McRae, Robert S. Sheldon |
| Abstract |
Vasovagal syncope is a common problem associated with a poor quality of life, which improves when the frequency of syncope is reduced. Effective pharmacological therapies for vasovagal syncope have been elusive. Midodrine is a pro-drug whose primary metabolite is an alpha-1 adrenoreceptor agonist. A few studies have suggested that it may be beneficial in syncope, but all have had significant methodological limitations. A placebo-controlled clinical trial of midodrine for the prevention of vasovagal syncope is needed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 44 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 14% |
| Student > Master | 6 | 14% |
| Professor | 5 | 11% |
| Student > Bachelor | 5 | 11% |
| Student > Doctoral Student | 3 | 7% |
| Other | 7 | 16% |
| Unknown | 12 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 59% |
| Nursing and Health Professions | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Psychology | 1 | 2% |
| Economics, Econometrics and Finance | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 13 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 May 2013.
All research outputs
#18,338,033
of 22,709,015 outputs
Outputs from Clinical Autonomic Research
#632
of 770 outputs
Outputs of similar age
#126,309
of 164,181 outputs
Outputs of similar age from Clinical Autonomic Research
#2
of 2 outputs
Altmetric has tracked 22,709,015 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 770 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,181 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.